US20070116764A1 - Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing - Google Patents
Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing Download PDFInfo
- Publication number
- US20070116764A1 US20070116764A1 US10/581,071 US58107104A US2007116764A1 US 20070116764 A1 US20070116764 A1 US 20070116764A1 US 58107104 A US58107104 A US 58107104A US 2007116764 A1 US2007116764 A1 US 2007116764A1
- Authority
- US
- United States
- Prior art keywords
- dosage form
- solid dosage
- polyethylene glycol
- printing
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 60
- 238000007639 printing Methods 0.000 title claims abstract description 50
- 238000011282 treatment Methods 0.000 title claims abstract description 35
- 239000000825 pharmaceutical preparation Substances 0.000 title description 7
- 239000007787 solid Substances 0.000 title description 3
- 239000007909 solid dosage form Substances 0.000 claims abstract description 77
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 61
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 61
- 238000005299 abrasion Methods 0.000 claims abstract description 31
- 239000007864 aqueous solution Substances 0.000 claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 239000011248 coating agent Substances 0.000 claims description 33
- 238000000576 coating method Methods 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000007941 film coated tablet Substances 0.000 claims description 11
- 239000004203 carnauba wax Substances 0.000 claims description 8
- 235000013869 carnauba wax Nutrition 0.000 claims description 8
- 235000013871 bee wax Nutrition 0.000 claims description 5
- 229940092738 beeswax Drugs 0.000 claims description 5
- 239000012166 beeswax Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 description 35
- -1 fatty acid ester Chemical class 0.000 description 19
- 239000007888 film coating Substances 0.000 description 17
- 238000009501 film coating Methods 0.000 description 17
- 239000002775 capsule Substances 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000003086 colorant Substances 0.000 description 12
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000001993 wax Substances 0.000 description 9
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 8
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 239000004014 plasticizer Substances 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000000873 masking effect Effects 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000005498 polishing Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002335 preservative effect Effects 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000009495 sugar coating Methods 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 229920001800 Shellac Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004208 shellac Substances 0.000 description 3
- 229940113147 shellac Drugs 0.000 description 3
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 3
- 235000013874 shellac Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004287 Dehydroacetic acid Substances 0.000 description 2
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920003143 Eudragit® FS 30 D Polymers 0.000 description 2
- 229920003139 Eudragit® L 100 Polymers 0.000 description 2
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 2
- 229920003141 Eudragit® S 100 Polymers 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 2
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940061632 dehydroacetic acid Drugs 0.000 description 2
- 235000019258 dehydroacetic acid Nutrition 0.000 description 2
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- WLDHEUZGFKACJH-ZRUFZDNISA-K Amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1\N=N\C1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-ZRUFZDNISA-K 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002891 anorexigenic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000006389 diacetylation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- JFVXEJADITYJHK-UHFFFAOYSA-L disodium 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [Na+].[Na+].Oc1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=Nc2ccc(cc2C1=O)S([O-])(=O)=O JFVXEJADITYJHK-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960005191 ferric oxide Drugs 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009477 fluid bed granulation Methods 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- SXQCTESRRZBPHJ-UHFFFAOYSA-M lissamine rhodamine Chemical compound [Na+].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O SXQCTESRRZBPHJ-UHFFFAOYSA-M 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- IWVKTOUOPHGZRX-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C IWVKTOUOPHGZRX-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000007645 offset printing Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960005382 phenolphthalein Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 238000007517 polishing process Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000009498 subcoating Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/007—Marking tablets or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41M—PRINTING, DUPLICATING, MARKING, OR COPYING PROCESSES; COLOUR PRINTING
- B41M3/00—Printing processes to produce particular kinds of printed work, e.g. patterns
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B41—PRINTING; LINING MACHINES; TYPEWRITERS; STAMPS
- B41M—PRINTING, DUPLICATING, MARKING, OR COPYING PROCESSES; COLOUR PRINTING
- B41M5/00—Duplicating or marking methods; Sheet materials for use therein
- B41M5/0011—Pre-treatment or treatment during printing of the recording material, e.g. heating, irradiating
Definitions
- the present invention relates to a method for treating a solid dosage form to improve the printability and abrasion resistance of a print to be produced on a surface of the solid dosage form, and a solid dosage form having improved abrasion resistance of a print or improved printability, which is afforded by the treatment.
- polishing with wax is often applied for the purpose of increasing the commercial value by glossy appearance, protecting a preparation from highly humid environment, preventing staining with coloring agents, improving slip property to facilitate handling in later operations of printing, inspection, packing and the like, and the like (e.g., Porter and two others, Pan Coating of Tablets and Granules, edited by Herbert A. Lieberman and one other, Pharmaceutical Dosage Forms Tablets, vol. 3, US, Marcel Dekker Inc., 1982, p. 92).
- Wax can be used by dissolving in an organic solvent such as chloroform/acetone and the like, or suspending in a dispersion medium such as alcohol and the like, or directly applied to the surface of a preparation as a fine powder.
- an organic solvent such as chloroform/acetone and the like
- a dispersion medium such as alcohol and the like
- the use of a suspension and a powder may cause non-uniform coating, possibly leading to inconvenience.
- polishing with a wax prior to printing may cause easy scratch of prints and stain of the preparation itself as well as containers, which in turn impairs identification function and also reduces the commercial value due to the defective appearance.
- some kind of wax provides too much polish that can cause printing failure, and decrease the product yield (e.g., U.S. Pat. No. 4,456,629 (column 1, lines 34-39)).
- the present inventors have conducted intensive studies in an attempt to solve the aforementioned problem and surprisingly found that the printability during printing and abrasion resistance of the print after printing of a solid dosage form can be remarkably improved, as compared to conventional tablets polished with a wax, by treating a surface thereof with a polyethylene glycol-containing aqueous solution prior to printing.
- the present inventors have conducted further studies based on these findings and completed the present invention.
- the present invention provides a method for treating a solid dosage form to improve the abrasion resistance of a print to be produced on a surface of the solid dosage form.
- a method for treating a solid dosage form to improve the abrasion resistance of a print to be produced on a surface of the solid dosage form is meant, for example, significantly reducing the degree of abrasion of the print produced on the solid dosage form as compared to a case free of such treatment, in the print abrasion test to be described in detail in the Examples to be mentioned below.
- the solid dosage form applicable to the treatment method of the present invention is not particularly limited in the dosage form as long as its surface can be printed on and, for example, tablet, capsule, troche, pill, suppository and the like can be mentioned.
- the method is particularly preferably applied to tablets and capsules.
- solid dosage form means not only pharmaceutical products but also any composition processed to have a certain dosage form of animal drug, agricultural chemical, fertilizer, sanitary products and the like.
- the active ingredient to be contained in the solid dosage form is not particularly limited.
- substances effective for the prophylaxis or treatment of various diseases which are exemplified by, but not limited to, substances having sleep-inducing action, tranquilizer activity, antibiotic activity, hypotensive action, antianginal activity, analgesic activity, anti-inflammatory activity, mental stabilizing action, diabetes treatment activity, diuretic action, anticholine activity, antihyperacidic action, antiepileptic action, ACE inhibitory activity, ⁇ -receptor antagonistic or agonistic activity, anesthetic action, anorexigenic action, antiarrhythmic action, antidepressive action, anticoagulant activity, anti diarrheal action, antihistaminic activity, antimalarial action, antitumor activity, immunosuppressive activity, anti-Parkinson's syndrome action, antipsychotic action, antiplatelet activity, antihyperlipidemic action and the like, and the like, substance having detergent action, substances having flavoring, fertilizer, and deodorizing actions, animal/p
- the solid dosage form of the present invention can contain a carrier acceptable for the use of the solid dosage form, together with the active ingredient.
- a pharmaceutical preparation for example, it can contain a pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier various organic or inorganic carriers conventionally used as preparation materials are used and, for example, excipient, lubricant, binder, disintegrant, thickener and the like are appropriately added in suitable amounts.
- additives such as preservative, antioxidant, coloring agent, sweetening agent and the like can also be used.
- excipient examples include, but are not limited to, lactose, sucrose, glucose, maltose, corn starch, flour starch, mannitol, xylitol, sorbitol, maltitol, erythritol, lactitol, palatinit, crystalline cellulose, light anhydrous silicic acid, dextrin, carboxymethylstarch, gelatin, synthesis aluminum silicate, magnesium alumino metesilicate, magnesium oxide, calcium phosphate, calcium carbonate, calcium sulfate and the like.
- lubricant examples include, but are not limited to, stearic acid, magnesium stearate, calcium stearate, talc, waxes, DL-leucine, sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol, aerosil (usable as antistatic agent) and the like.
- binder examples include, but are not limited to, gelatin, pullulan, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), methylcellulose (MC), crystalline cellulose, polyvinylpyrrolidone (PVP), polyethylene glycol, gum arabic, dextran, polyvinyl alcohol (PVA), starch paste and the like.
- disintegrant examples include, but are not limited to, carboxymethylcellulose, calcium carboxymethylcellulose, low-substituted hydroxypropylcellulose, crosslinking polyvinylpyrrolidone, carmellose sodium, croscarmellose sodium, sodium carboxymethyl starch, cation exchange resin, partially pregelatinized starch, corn starch and the like.
- thickener examples include, but are not limited to, natural rubbers, cellulose derivative, acrylic acid polymer and the like.
- preservative examples include, but are not limited to, p-hydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- antioxidants examples include, but are not limited to, sulfite, ascorbic acid and their alkali metal salts, alkaline earth metal salts and the like.
- coloring agent examples include, but are not limited to, synthetic coloring agents applicable to pharmaceutical products (e.g., sunset yellow etc. and aluminum lake thereof and the like), yellow ferric oxide, red ferric oxide, riboflavin, riboflavin organic acid esters (e.g., riboflavin butyric acid ester), phosphoric acid riboflavin or alkali metal salt thereof, alkaline earth metal salt, phenol phthalein, titanium oxide and the like.
- synthetic coloring agents applicable to pharmaceutical products e.g., sunset yellow etc. and aluminum lake thereof and the like
- yellow ferric oxide red ferric oxide
- riboflavin riboflavin organic acid esters
- phosphoric acid riboflavin or alkali metal salt thereof alkaline earth metal salt
- titanium oxide and the like can be mentioned.
- sweetening agent examples include, but are not limited to, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like.
- the solid dosage form of the present invention can be formulated into a dosage form suitable for oral administration, which is exemplified by, but not limited to, tablet, capsule and the like or parenteral administration such as suppository and the like, by processing the above-mentioned active ingredient and a suitable carrier according to a method known per se.
- Tablets can be coated by a method known per se for the purpose of masking a smell or taste, stabilizing components, maintaining efficacy and the like.
- the coating can be largely divided into sugar coating and film coating (including enteric coating and the like) according to its kind.
- sucrose As a coating agent for sugar coating, sucrose is generally used. To enhance the binding property of a sugar coating layer and increase the mechanical strength, gelatin, gum arabic, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, sodium starchglycolate, crystalline cellulose, polyvinylpyrrolidone, polyvinyl alcohol, sodium alginate and the like can be added. Furthermore, as an excipient or anti-tack agent, talc, precipitated calcium carbonate, kaolin and the like are used, and, for masking or shading of color, a masking agent such as titanium oxide and the like are used.
- the film coating agent for example, hydroxypropylmethylcellulose, ethylcellulose, hydroxypropylcellulose, tween80, and dyes such as titanium oxide, ferric oxide (e.g., red ferric oxide, yellow ferric oxide) and the like are used. Moreover, photostability and the like can be improved by adding a masking agent and the like.
- These film coating formulations may contain, where necessary, talc and other excipients applicable to pharmaceutical products.
- a base agent aiming at enteric coating and controlled release may be used besides those used for masking a taste, enhancing photostability or improving appearance.
- hydroxypropylcellulose HPC
- hydroxypropylmethylcellulose HPMC
- polyvinylpyrrolidone PVP
- ethylcellulose polyvinyl acetal diethylamino acetate
- cellulose acetate phthalate methacrylic acid copolymers (e.g., methyl methacrylate-methacryl acid copolymers (Eudragit L100 or S100, manufactured by Rohm), methacrylic acid-ethyl acrylate copolymers (Eudragit L100-55, L30D-55), methacrylic acid-methyl acrylate-methyl methacrylate copolymers (Eudragit FS30D, manufactured by Rohm)), hydroxypropylmethylcellulose phthalate (HP-55, HP-50, manufactured by Shin-Etsu Chemical Co., Ltd.), carboxymethylethylcellulose (CMEC, manufactured by Freund Corporation), hydroxypropylcellulose acetate succinate (HPC), hydroxypropylcellulose a
- hydroxypropylmethylcellulose phthalates HP-55, HP-50, manufactured by Shin-Etsu Chemical Co., Ltd.
- cellulose acetate phthalate carboxymethylethylcellulose (CMEC, manufactured by Freund Corporation)
- CMEC carboxymethylethylcellulose
- methyl methacrylate-methacrylic acid copolymers Eudragit L100 or S100, manufactured by Rohm
- methacrylic acid-ethyl acrylate copolymers Eudragit L100-55, L30D-55
- methacrylic acid-methyl acrylate-methyl methacrylate copolymer Eudragit FS30D, manufactured by Rohm
- hydroxypropylcellulose acetate succinate HPMCAS, manufactured by Shin-Etsu Chemical Co., Ltd.
- polyvinyl acetate phthalate shellac and the like
- the coating agents may be used alone or in combination as necessary.
- plasticizer, stabilizer and the like such as polyethylene glycol, dibutyl sebacate, diethyl phthalate, triacetine, triethyl citrate, copolyvidon and the like may be used for coating.
- a method known per se such as a pan coating method using a perforated coating system (e.g., Hicoater (trademark); Freund Corporation) and the like using a coating pan, a fluid bed coating method using a fluid bed granulation coating system (e.g., flow coater (trademark); Freund Corporation) and the like, is employed.
- a perforated coating system e.g., Hicoater (trademark); Freund Corporation
- a fluid bed coating method using a fluid bed granulation coating system e.g., flow coater (trademark); Freund Corporation
- Capsules can be produced by packing the above-mentioned active ingredient powder, or a powder mixture of the active ingredient and the above-mentioned carrier, or fine granules or granules obtained by kneading or granulating the powder mixture and the like in a suitable capsule.
- the packed material (particularly fine particles or granules) may be film-coated as necessary, in a similar manner as that mentioned above with regard to the tablet.
- the capsule one containing polyhydric alcohol such as glycerol, propylene glycol and the like or saccharide such as mannitol, sorbit and the like as a plasticizer in gelatin, which is molded suitably can be mentioned.
- the capsule may further contain a coloring agent and a preservative similar to those mentioned above.
- the treatment method of the present invention may be applied to a capsule filled with the packing material such as an active ingredient and the like.
- an empty capsule may be subjected to the treatment method of the present invention, printed and filled with a packing material to give a finished preparation.
- the treatment method of the present invention can also be applied not only to the above-mentioned solid dosage form but also any solid composition desired to carry a print on its surface such as a food (e.g., sugar coated chocolate, gum, supplement and the like) and the like, particularly a solid composition requiring or desirably subjected to a treatment for improving the slip property and gloss.
- a food e.g., sugar coated chocolate, gum, supplement and the like
- a solid composition requiring or desirably subjected to a treatment for improving the slip property and gloss.
- the treatment method of the present invention is characterized by a treatment of a surface of the solid dosage form with a polyethylene glycol-containing aqueous solution before printing.
- treatment is meant “to apply” and refers to bringing a polyethylene glycol-containing aqueous solution into contact with the surface of a solid dosage form after treatment, such that polyethylene glycol remains on the surface.
- Polyethylene glycol to be used in the present invention is not particularly limited as long as it is not subject to any limitation due to other reasons (e.g., range acceptable as a pharmaceutical additive when the solid dosage form is a pharmaceutical preparation).
- polyethylene glycol is desirably present as a solid at a temperature of the environment (e.g., 0 to 40° C., 10 to 30° C., 15 to 25° C.) where the solid dosage form is preserved.
- a temperature of the environment e.g., 0 to 40° C., 10 to 30° C., 15 to 25° C.
- one having an average molecular weight of about not less than 1,000, more preferably about 3,000 to about 9,000 can be mentioned.
- two or more kinds of polyethylene glycol having different average molecular weights may be used in a mixture.
- the average molecular weight of polyethylene glycol is measured by a method according to the measurement method of the average molecular weight of macrogol 4000 in the Japan Pharmacopoeia fourteenth Edition (hereinafter sometimes to be abbreviated simply as the Japan Pharmacopoeia).
- the concentration of polyethylene glycol in the polyethylene glycol-containing aqueous solution is not particularly limited as long as it ensures that polyethylene glycol remains on the surface of a solid dosage form after treatment in an amount sufficient to improve the abrasion resistance of a print to be produced on said surface.
- it is about 1 to about 20 wt %, preferably about 5 to about 15 wt %.
- the polyethylene glycol-containing aqueous solution can contain a component other than polyethylene glycol within the range free of a bad influence on the property of a print to be produced on the surface of a solid dosage form.
- the polyethylene glycol-containing aqueous solution contains a film coating agent since the solution also functions as a film coating liquid, as mentioned above.
- the film coating agent for example, those capable of being dispersed in a water-soluble or aqueous solution can be mentioned, from the above-mentioned film coating agents.
- the polyethylene glycol-containing aqueous solution can further contain a preparation additive as necessary, such as stabilizer, lubricant, preservative, antioxidant, coloring agent, sweetening agent and the like.
- a preparation additive as necessary, such as stabilizer, lubricant, preservative, antioxidant, coloring agent, sweetening agent and the like.
- stabilizer for example, tartaric acid, citric acid, succinic acid, fumaric acid, maleic acid and the like can be mentioned.
- lubricant for example, talc, titanium oxide, magnesium stearate, calcium stearate, light anhydrous silicic acid and the like can be mentioned.
- the preservative for example, p-hydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like can be mentioned.
- the antioxidant for example, sulfite, ascorbate and the like can be mentioned.
- the coloring agent for example, water-soluble food tar colors (e.g., food dyes such as Food Red No. 2 and No. 3, Food Yellow No. 4 and No. 5, Food Blue No. 1 and No. 2 and the like), water insoluble lake colors (e.g., aluminum salts of the aforementioned water-soluble food tar colors), natural colors (e.g., B-carotene, chlorophyll, ferric oxide) and the like can be mentioned.
- the sweetening agent for example, sodium saccharin, dipotassium glycyrrhizinate, aspartame, stevia and the like can be mentioned.
- the film coating liquid can contain a plasticizer to control the softening temperature of the coating agent.
- polyethylene glycol-containing aqueous solution is a film coating liquid
- polyethylene glycol itself can function as a plasticizer.
- a polyethylene glycol-containing aqueous solution having a concentration necessary for improving the abrasion resistance of a print to be produced on the surface of a solid dosage form is sufficient to function as a plasticizer.
- plasticizers such as acetyltributyl citrate, acetyltriethyl citrate, castor oil, diacetylation monoglyceride, dibutyl sebacate, diethyl phthalate, glycerol, mono- or di-acetylation monoglyceride, propyleneglycol, triacetine, triethyl citrate and the like may be further added.
- plasticizers such as acetyltributyl citrate, acetyltriethyl citrate, castor oil, diacetylation monoglyceride, dibutyl sebacate, diethyl phthalate, glycerol, mono- or di-acetylation monoglyceride, propyleneglycol, triacetine, triethyl citrate and the like may be further added.
- the proportion of polyethylene glycol in the whole components is about 1 to about 30 wt %, preferably about 10 to about 20 wt %.
- a treatment of the surface of a solid dosage form with a polyethylene glycol-containing aqueous solution various coating methods generally used in the field of preparations can be employed.
- spray coating is applied using a coating pan, a fluid bed coating system and the like.
- sugar-coated tablets for example, after completion of each step of sugar coating (i.e., waterproof coating, under coating, sub-coating, coloring, finishing), tablets are transferred to a cloth polishing pan, a predetermined amount of a polyethylene glycol-containing aqueous solution is sprayed or poured thereon while rotating the pan, or a polyethylene glycol-containing aqueous solution is sprayed or poured thereon once to several times while rotating the pan until it reaches a predetermined coating weight.
- sugar coating i.e., waterproof coating, under coating, sub-coating, coloring, finishing
- a polyethylene glycol-containing aqueous solution is sprayed with a compressed air from a spray nozzle in the coating pan used for the film coating while rotating the pan, and the surface of the tablets is dried by heated air supplied.
- a polyethylene glycol-containing aqueous solution is sprayed from a spray nozzle while floating or fluidizing the tablets with an air flow and the surface of the tablets is dried with the air flow.
- the polyethylene glycol-containing aqueous solution is sprayed in a predetermined amount, or the above-mentioned operation is repeated until a predetermined coat weight is achieved.
- a method employed for conventional film coating can be used similarly.
- this treatment is applied after filling packing materials such as an active ingredient and the like, powder of the packing materials attached to the surface of the capsule during the filling is preferably removed with a conventional capsule polishing machine before the treatment.
- the weight of the coating film formed by the treatment method of the present invention is not particularly limited as long as it ensures that polyethylene glycol remains on the surface of a solid dosage form after treatment in an amount sufficient to improve the abrasion resistance of a print to be produced on said surface.
- it is appropriately selected from the range that makes the weight ratio of the amount of polyethylene glycol to be added by this treatment to the finished preparation fall within the range of about 0.01 to about 1.0%, more preferably about 0.05 to about 0.7%.
- the treatment method of the present invention can not only improve the abrasion resistance of a print to be produced on the surface of a solid dosage form, but also reduce the frequency of printing failure (i.e., printing failure rate) during printing such as incomplete print, printing stain and the like, and advantageously further improve the printing performance as a whole.
- printing failure i.e., printing failure rate
- the present invention also relates to a production method of a solid dosage form having a print on its surface, which comprises treating the surface of the solid dosage form with a polyethylene glycol-containing aqueous solution and then printing on said surface.
- the treatment with a polyethylene glycol-containing aqueous solution can be applied as mentioned above.
- a method conventionally used in the art can be employed.
- a solid dosage form delivery mechanism of a printing machine any type can be used, including a slot type, a drum type, a link type and the like, and an appropriate type can be selected according to the manufacturing scale and the like.
- the printing method is not particularly limited, either, a photogravure offset printing method is often used.
- a photogravure roll engraved with an identification code, a symbol and the like during a photomechanical process is rotated in an ink tank to attach the ink, and redundant ink is scraped off with a blade (thin-bladed knife).
- the ink remaining in the engraving (concave) is transferred onto a rubber offset roll, and then transferred onto the solid dosage form in a printing section to complete the printing.
- a tablet (capsule) printing machine commercially available ones from Markem Corporation, Hartnett, Matsuoka Machinery Works Co., Ltd, Qualicaps Co., Ltd. and the like can be used.
- the ink to be used for printing is not particularly limited as long as it is harmless, it is desirably quick-drying, and has high abrasion resistance after drying.
- titanium oxide, carbon black, iron oxide, tar dyes e.g., acidic colors such as Red No. 2, Red No. 3, Red No. 102, Red No. 104-(1), Red No. 105-(1), Red No. 106, Yellow No. 4, Yellow No. 5, Green No. 5, Blue No. 1, Blue No. 2 and the like
- acidic colors such as Red No. 2, Red No. 3, Red No. 102, Red No. 104-(1), Red No. 105-(1), Red No. 106, Yellow No. 4, Yellow No. 5, Green No. 5, Blue No. 1, Blue No. 2 and the like
- the base agent moreover, shellac and the like are used and, as the solvent, ethanol, n-butanol, isopropanol and the like are used.
- the solid dosage form with a print on its surface which is produced by the above-mentioned method, has novel and useful characteristic in that it shows remarkably improved abrasion resistance of prints as compared to conventional preparations obtained by applying, before printing, a polishing treatment with a wax solution using an organic solvent or a powder wax or a wax-like substance. Accordingly, the present invention also provides a solid dosage form obtained by the above-mentioned method, which has a print on its surface.
- the solid dosage form of the present invention can be conferred a desirable characteristic of superior abrasion resistance of a print produced on its surface, due to the presence of a coating film containing polyethylene glycol on the surface of the solid dosage form.
- the “coating film” does not need to completely cover the surface of a solid dosage form, as long as polyethylene glycol is substantially uniformly present at least on the area to be printed on.
- the “coating film” may be in the state where a number of miniature films attach to the surface of a solid dosage form.
- substantially uniform is meant being uniform to a degree sufficient to improve the abrasion resistance of the print. Therefore, the solid dosage form of the present invention is not restricted to the above-mentioned method, as long as it has the above-mentioned surface structure and superior abrasion resistance of the print, and may be produced by any method.
- the solid dosage form of the present invention does not contain bees wax and carnauba wax in the coating film containing polyethylene glycol.
- the solid dosage form of the present invention can be administered to the subject in the same manner as in conventional solid dosage forms.
- plain tablet 130.0 (containing 4 mg of active ingredient) hydroxypropylmethylcellulose 3.74 (74.8%) (TC-5; trademark) copolyvidon 0.75 (15.0%) titanium oxide 0.5 (10.0%) yellow ferric oxide 0.01 (0.2%) total 135.0
- Plain tablets were placed in a coating machine (Driacoater (Powrex Corporation) or Hicoater (Freund Corporation)), a film coating liquid containing TC-5, copolyvidon, titanium oxide and yellow ferric oxide at the above-mentioned weight ratios was sprayed with a spray nozzle while rotating the pan, and the tablets were dried by heated air supplied. This operation was repeated until the above-mentioned coating weight was achieved.
- a coating machine Driacoater (Powrex Corporation) or Hicoater (Freund Corporation)
- a film coating liquid containing TC-5, copolyvidon, titanium oxide and yellow ferric oxide at the above-mentioned weight ratios was sprayed with a spray nozzle while rotating the pan, and the tablets were dried by heated air supplied. This operation was repeated until the above-mentioned coating weight was achieved.
- Pre-printing Treatment with Polyethylene Glycol-containing Aqueous Solution Formulation (Unit: mg) Prepar. Ex. 1
- Prepar. Ex. 2 Comp. Ex. film-coated tablet 135.0 135.0 135.0 (Reference Example)
- MACROGOL 4000 0.1 the Japan Pharmacopoeia
- MACROGOL 6000 0.1 the Japan Pharmacopoeia
- water (0.9) (0.9) carnauba wax 0.008 sorbitan mono-oleate 0.04 n-hexane (0.9625)
- the film-coated tablets (6,000 tablets, 810 g) obtained in the above-mentioned Reference Example were placed in a Hicoater (Freund Corporation), and a 10 wt % aqueous solution of MACROGOL 4000 (the Japan Pharmacopoeia; molecular weight 2,600-3,800) (Preparation Example 1) or MACROGOL 6000 (the Japan Pharmacopoeia; molecular weight 7,300-9,300) (Preparation Example 2) in total 6.0 g, or a 0.79 wt % carnauba wax n-hexane solution (Comparative Example) in total 6.063 g was sprayed with a spray nozzle while rotating the pan to give respective tablets having the above-mentioned formulations.
- MACROGOL 4000 the Japan Pharmacopoeia; molecular weight 2,600-3,800
- MACROGOL 6000 the Japan Pharmacopoeia; molecular weight 7,300-9,300
- printability and abrasion resistance of a print to be produced on a surface of the solid dosage form can be improved, and as a result, identification function of the solid dosage form can be maintained for a long time and good appearance is not impaired, and a solid dosage form with a high commercial value can be provided.
- the method for treating a solid dosage form of the present invention provides an effect of remarkably improved printability and abrasion resistance of the solid dosage form by treating, before printing, the surface of the solid dosage form with a polyethylene glycol-containing aqueous solution.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
The present invention provides a method for treating a solid dosage form to improve the printability and abrasion resistance of a print to be produced on a surface of the solid dosage form, which includes treating the surface of the solid dosage form with a polyethylene glycol-containing aqueous solution before printing; a production method of a solid dosage form with a printed surface, which includes printing on the surface after the aforementioned treatment; and a solid dosage form having a print improved in abrasion resistance on its surface, which can be obtained by the aforementioned production method.
Description
- The present invention relates to a method for treating a solid dosage form to improve the printability and abrasion resistance of a print to be produced on a surface of the solid dosage form, and a solid dosage form having improved abrasion resistance of a print or improved printability, which is afforded by the treatment.
- There are many kinds of tablets and capsules that resemble one another in the size, color tone and shape. To identify each preparation, a company name, a company mark, a product name, ingredient contents and the like are often coded and directly imprinted on the preparation. For imprinting, engraving and printing are available. While engraving is employed for plain tablets free of coating, a subset of film-coated tablets and the like, printing is employed for many film-coated tablets, sugar-coated tablets, capsules and the like.
- For tablets and capsules, polishing with wax (in this specification, it means “wax” in a narrow sense, namely, fatty acid ester of higher alcohol; examples: carnauba wax, bees wax and the like) is often applied for the purpose of increasing the commercial value by glossy appearance, protecting a preparation from highly humid environment, preventing staining with coloring agents, improving slip property to facilitate handling in later operations of printing, inspection, packing and the like, and the like (e.g., Porter and two others, Pan Coating of Tablets and Granules, edited by Herbert A. Lieberman and one other, Pharmaceutical Dosage Forms Tablets, vol. 3, US, Marcel Dekker Inc., 1982, p. 92). Wax can be used by dissolving in an organic solvent such as chloroform/acetone and the like, or suspending in a dispersion medium such as alcohol and the like, or directly applied to the surface of a preparation as a fine powder. However, it is desirable to avoid use of an organic solvent in view of the safety issue caused by a residual solvent, a large scale facility required to prevent accident and environmental pollution, and the like. Moreover, the use of a suspension and a powder may cause non-uniform coating, possibly leading to inconvenience.
- Furthermore, polishing with a wax prior to printing may cause easy scratch of prints and stain of the preparation itself as well as containers, which in turn impairs identification function and also reduces the commercial value due to the defective appearance. In addition, some kind of wax provides too much polish that can cause printing failure, and decrease the product yield (e.g., U.S. Pat. No. 4,456,629 (column 1, lines 34-39)).
- It is therefore an object of the present invention to provide a method of polishing a solid dosage form without using an organic solvent, which can improve and abrasion resistance of a print and printability of the solid dosage form, and a solid dosage form improved in the abrasion resistance of a print and/or printability based on the method.
- The present inventors have conducted intensive studies in an attempt to solve the aforementioned problem and surprisingly found that the printability during printing and abrasion resistance of the print after printing of a solid dosage form can be remarkably improved, as compared to conventional tablets polished with a wax, by treating a surface thereof with a polyethylene glycol-containing aqueous solution prior to printing. The present inventors have conducted further studies based on these findings and completed the present invention.
- Accordingly, the present invention provides
- [1] a treatment method for improving printability and/or abrasion resistance of a print to be produced on a surface of a solid dosage form, which comprises treating said surface with a polyethylene glycol-containing aqueous solution before printing,
- [2] the method of the above-mentioned [1], wherein polyethylene glycol has an average molecular weight of not less than about 1,000,
- [3] the method of the above-mentioned [1], wherein polyethylene glycol has an average molecular weight of about 3,000 to about 9,000,
- [4] the method of the above-mentioned [1], wherein the amount of polyethylene glycol to be added by the treatment is about 0.01% to about 1.0% in a weight ratio to the finished preparation,
- [5] the method of the above-mentioned [1], wherein the solid dosage form is a film-coated tablet,
- [6] a method for producing a solid dosage form with a printed surface, which comprises treating the surface of the solid dosage form with a polyethylene glycol-containing aqueous solution and then printing on said surface,
- [7] the method of the above-mentioned [6], wherein polyethylene glycol has an average molecular weight of not less than about 1,000,
- [8] the method of the above-mentioned [6], wherein polyethylene glycol has an average molecular weight of about 3,000 to about 9,000,
- [9] the method of the above-mentioned [6], wherein the amount of polyethylene glycol to be added by the treatment is about 0.01% to about 1.0% in a weight ratio to the finished preparation,
- [10] the method of the above-mentioned [6], wherein the solid dosage form is a film-coated tablet,
- [11] a solid dosage form treated by the method of any of the above-mentioned [1] to [5],
- [12] a solid dosage form with a printed surface, which can be obtained by any of the above-mentioned [6] to [10],
- [13] a solid dosage form which has a coating film comprising polyethylene glycol but free of bees wax and carnauba wax on its surface, and is printed on the surface of the coating film, and
- [14] a solid dosage form which has a coating comprising polyethylene glycol but free of bees wax and carnauba wax on its surface, and is printed on the surface of the coating.
- The present invention provides a method for treating a solid dosage form to improve the abrasion resistance of a print to be produced on a surface of the solid dosage form. As used herein, by “to improve the abrasion resistance of a print” is meant, for example, significantly reducing the degree of abrasion of the print produced on the solid dosage form as compared to a case free of such treatment, in the print abrasion test to be described in detail in the Examples to be mentioned below.
- The solid dosage form applicable to the treatment method of the present invention is not particularly limited in the dosage form as long as its surface can be printed on and, for example, tablet, capsule, troche, pill, suppository and the like can be mentioned. In view of the necessity of imprinting by printing, the method is particularly preferably applied to tablets and capsules.
- In this specification, the “solid dosage form” means not only pharmaceutical products but also any composition processed to have a certain dosage form of animal drug, agricultural chemical, fertilizer, sanitary products and the like.
- The active ingredient to be contained in the solid dosage form is not particularly limited. For example, substances effective for the prophylaxis or treatment of various diseases, which are exemplified by, but not limited to, substances having sleep-inducing action, tranquilizer activity, antibiotic activity, hypotensive action, antianginal activity, analgesic activity, anti-inflammatory activity, mental stabilizing action, diabetes treatment activity, diuretic action, anticholine activity, antihyperacidic action, antiepileptic action, ACE inhibitory activity, β-receptor antagonistic or agonistic activity, anesthetic action, anorexigenic action, antiarrhythmic action, antidepressive action, anticoagulant activity, anti diarrheal action, antihistaminic activity, antimalarial action, antitumor activity, immunosuppressive activity, anti-Parkinson's syndrome action, antipsychotic action, antiplatelet activity, antihyperlipidemic action and the like, and the like, substance having detergent action, substances having flavoring, fertilizer, and deodorizing actions, animal/pest exterminating substances, substances having insecticidal action, substances having herbicidal action, plant growth regulators and the like.
- Where necessary, the solid dosage form of the present invention can contain a carrier acceptable for the use of the solid dosage form, together with the active ingredient. In the case of a pharmaceutical preparation, for example, it can contain a pharmaceutically acceptable carrier. As the pharmaceutically acceptable carrier, various organic or inorganic carriers conventionally used as preparation materials are used and, for example, excipient, lubricant, binder, disintegrant, thickener and the like are appropriately added in suitable amounts. Where necessary, additives such as preservative, antioxidant, coloring agent, sweetening agent and the like can also be used.
- Examples of the excipient include, but are not limited to, lactose, sucrose, glucose, maltose, corn starch, flour starch, mannitol, xylitol, sorbitol, maltitol, erythritol, lactitol, palatinit, crystalline cellulose, light anhydrous silicic acid, dextrin, carboxymethylstarch, gelatin, synthesis aluminum silicate, magnesium alumino metesilicate, magnesium oxide, calcium phosphate, calcium carbonate, calcium sulfate and the like.
- Examples of the lubricant include, but are not limited to, stearic acid, magnesium stearate, calcium stearate, talc, waxes, DL-leucine, sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycol, aerosil (usable as antistatic agent) and the like.
- Examples of the binder include, but are not limited to, gelatin, pullulan, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), methylcellulose (MC), crystalline cellulose, polyvinylpyrrolidone (PVP), polyethylene glycol, gum arabic, dextran, polyvinyl alcohol (PVA), starch paste and the like.
- Examples of the disintegrant include, but are not limited to, carboxymethylcellulose, calcium carboxymethylcellulose, low-substituted hydroxypropylcellulose, crosslinking polyvinylpyrrolidone, carmellose sodium, croscarmellose sodium, sodium carboxymethyl starch, cation exchange resin, partially pregelatinized starch, corn starch and the like.
- Examples of the thickener include, but are not limited to, natural rubbers, cellulose derivative, acrylic acid polymer and the like.
- Examples of the preservative include, but are not limited to, p-hydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- Examples of the antioxidant include, but are not limited to, sulfite, ascorbic acid and their alkali metal salts, alkaline earth metal salts and the like.
- Examples of the coloring agent include, but are not limited to, synthetic coloring agents applicable to pharmaceutical products (e.g., sunset yellow etc. and aluminum lake thereof and the like), yellow ferric oxide, red ferric oxide, riboflavin, riboflavin organic acid esters (e.g., riboflavin butyric acid ester), phosphoric acid riboflavin or alkali metal salt thereof, alkaline earth metal salt, phenol phthalein, titanium oxide and the like. As the light shielding agent, titanium oxide and the like can be mentioned.
- Examples of the sweetening agent include, but are not limited to, saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like.
- The solid dosage form of the present invention can be formulated into a dosage form suitable for oral administration, which is exemplified by, but not limited to, tablet, capsule and the like or parenteral administration such as suppository and the like, by processing the above-mentioned active ingredient and a suitable carrier according to a method known per se.
- Tablets can be coated by a method known per se for the purpose of masking a smell or taste, stabilizing components, maintaining efficacy and the like. The coating can be largely divided into sugar coating and film coating (including enteric coating and the like) according to its kind.
- As a coating agent for sugar coating, sucrose is generally used. To enhance the binding property of a sugar coating layer and increase the mechanical strength, gelatin, gum arabic, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, sodium starchglycolate, crystalline cellulose, polyvinylpyrrolidone, polyvinyl alcohol, sodium alginate and the like can be added. Furthermore, as an excipient or anti-tack agent, talc, precipitated calcium carbonate, kaolin and the like are used, and, for masking or shading of color, a masking agent such as titanium oxide and the like are used.
- As the film coating agent, for example, hydroxypropylmethylcellulose, ethylcellulose, hydroxypropylcellulose, tween80, and dyes such as titanium oxide, ferric oxide (e.g., red ferric oxide, yellow ferric oxide) and the like are used. Moreover, photostability and the like can be improved by adding a masking agent and the like. These film coating formulations may contain, where necessary, talc and other excipients applicable to pharmaceutical products. As the film coating agent, a base agent aiming at enteric coating and controlled release may be used besides those used for masking a taste, enhancing photostability or improving appearance. As a base agent for the film coating, hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), polyvinylpyrrolidone (PVP), ethylcellulose, polyvinyl acetal diethylamino acetate, cellulose acetate phthalate, methacrylic acid copolymers (e.g., methyl methacrylate-methacryl acid copolymers (Eudragit L100 or S100, manufactured by Rohm), methacrylic acid-ethyl acrylate copolymers (Eudragit L100-55, L30D-55), methacrylic acid-methyl acrylate-methyl methacrylate copolymers (Eudragit FS30D, manufactured by Rohm)), hydroxypropylmethylcellulose phthalate (HP-55, HP-50, manufactured by Shin-Etsu Chemical Co., Ltd.), carboxymethylethylcellulose (CMEC, manufactured by Freund Corporation), hydroxypropylcellulose acetate succinate (HPMCAS, manufactured by Shin-Etsu Chemical Co., Ltd.), polyvinyl acetate phthalate, shellac and the like can be used. They may be used alone, or at least two or more kinds of polymers may be applied in combination, or at least two or more kinds of polymers may be applied successively.
- Of these, as a coating material for controlling the release of the active ingredient in a pH-dependent manner, hydroxypropylmethylcellulose phthalates (HP-55, HP-50, manufactured by Shin-Etsu Chemical Co., Ltd.), cellulose acetate phthalate, carboxymethylethylcellulose (CMEC, manufactured by Freund Corporation), methyl methacrylate-methacrylic acid copolymers (Eudragit L100 or S100, manufactured by Rohm), methacrylic acid-ethyl acrylate copolymers (Eudragit L100-55, L30D-55), methacrylic acid-methyl acrylate-methyl methacrylate copolymer (Eudragit FS30D, manufactured by Rohm), hydroxypropylcellulose acetate succinate (HPMCAS, manufactured by Shin-Etsu Chemical Co., Ltd.), polyvinyl acetate phthalate, shellac and the like can be used.
- The coating agents may be used alone or in combination as necessary. Where necessary, plasticizer, stabilizer and the like such as polyethylene glycol, dibutyl sebacate, diethyl phthalate, triacetine, triethyl citrate, copolyvidon and the like may be used for coating.
- For coating, a method known per se, such as a pan coating method using a perforated coating system (e.g., Hicoater (trademark); Freund Corporation) and the like using a coating pan, a fluid bed coating method using a fluid bed granulation coating system (e.g., flow coater (trademark); Freund Corporation) and the like, is employed.
- Capsules can be produced by packing the above-mentioned active ingredient powder, or a powder mixture of the active ingredient and the above-mentioned carrier, or fine granules or granules obtained by kneading or granulating the powder mixture and the like in a suitable capsule. The packed material (particularly fine particles or granules) may be film-coated as necessary, in a similar manner as that mentioned above with regard to the tablet.
- As the capsule, one containing polyhydric alcohol such as glycerol, propylene glycol and the like or saccharide such as mannitol, sorbit and the like as a plasticizer in gelatin, which is molded suitably can be mentioned. Where necessary, the capsule may further contain a coloring agent and a preservative similar to those mentioned above.
- The treatment method of the present invention may be applied to a capsule filled with the packing material such as an active ingredient and the like. Alternatively, an empty capsule may be subjected to the treatment method of the present invention, printed and filled with a packing material to give a finished preparation.
- The treatment method of the present invention can also be applied not only to the above-mentioned solid dosage form but also any solid composition desired to carry a print on its surface such as a food (e.g., sugar coated chocolate, gum, supplement and the like) and the like, particularly a solid composition requiring or desirably subjected to a treatment for improving the slip property and gloss.
- The treatment method of the present invention is characterized by a treatment of a surface of the solid dosage form with a polyethylene glycol-containing aqueous solution before printing. As used herein, by the “treatment” is meant “to apply” and refers to bringing a polyethylene glycol-containing aqueous solution into contact with the surface of a solid dosage form after treatment, such that polyethylene glycol remains on the surface.
- Polyethylene glycol to be used in the present invention is not particularly limited as long as it is not subject to any limitation due to other reasons (e.g., range acceptable as a pharmaceutical additive when the solid dosage form is a pharmaceutical preparation). In consideration of the object of the present invention to improve durability of a print, however, polyethylene glycol is desirably present as a solid at a temperature of the environment (e.g., 0 to 40° C., 10 to 30° C., 15 to 25° C.) where the solid dosage form is preserved. For example, one having an average molecular weight of about not less than 1,000, more preferably about 3,000 to about 9,000, can be mentioned. In addition, two or more kinds of polyethylene glycol having different average molecular weights may be used in a mixture.
- The average molecular weight of polyethylene glycol is measured by a method according to the measurement method of the average molecular weight of macrogol 4000 in the Japan Pharmacopoeia fourteenth Edition (hereinafter sometimes to be abbreviated simply as the Japan Pharmacopoeia).
- The concentration of polyethylene glycol in the polyethylene glycol-containing aqueous solution is not particularly limited as long as it ensures that polyethylene glycol remains on the surface of a solid dosage form after treatment in an amount sufficient to improve the abrasion resistance of a print to be produced on said surface. For example, it is about 1 to about 20 wt %, preferably about 5 to about 15 wt %.
- The polyethylene glycol-containing aqueous solution can contain a component other than polyethylene glycol within the range free of a bad influence on the property of a print to be produced on the surface of a solid dosage form. As used herein, by the “property of a print” is meant properties including quantitative and qualitative characteristics during printing, such as abrasion resistance after printing, incidence of incomplete print, printing stain and the like (=rate of printing failure) and level of the printing failure. For example, when the treatment method of the present invention is applied to a plain tablet, the polyethylene glycol-containing aqueous solution contains a film coating agent since the solution also functions as a film coating liquid, as mentioned above. As the film coating agent, for example, those capable of being dispersed in a water-soluble or aqueous solution can be mentioned, from the above-mentioned film coating agents.
- In addition, the polyethylene glycol-containing aqueous solution can further contain a preparation additive as necessary, such as stabilizer, lubricant, preservative, antioxidant, coloring agent, sweetening agent and the like. As the stabilizer, for example, tartaric acid, citric acid, succinic acid, fumaric acid, maleic acid and the like can be mentioned. As the lubricant, for example, talc, titanium oxide, magnesium stearate, calcium stearate, light anhydrous silicic acid and the like can be mentioned. As the preservative, for example, p-hydroxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like can be mentioned. As the antioxidant, for example, sulfite, ascorbate and the like can be mentioned. As the coloring agent, for example, water-soluble food tar colors (e.g., food dyes such as Food Red No. 2 and No. 3, Food Yellow No. 4 and No. 5, Food Blue No. 1 and No. 2 and the like), water insoluble lake colors (e.g., aluminum salts of the aforementioned water-soluble food tar colors), natural colors (e.g., B-carotene, chlorophyll, ferric oxide) and the like can be mentioned. As the sweetening agent, for example, sodium saccharin, dipotassium glycyrrhizinate, aspartame, stevia and the like can be mentioned.
- As mentioned above, the film coating liquid can contain a plasticizer to control the softening temperature of the coating agent. When the polyethylene glycol-containing aqueous solution is a film coating liquid, polyethylene glycol itself can function as a plasticizer. A polyethylene glycol-containing aqueous solution having a concentration necessary for improving the abrasion resistance of a print to be produced on the surface of a solid dosage form is sufficient to function as a plasticizer. When desired, other plasticizers, such as acetyltributyl citrate, acetyltriethyl citrate, castor oil, diacetylation monoglyceride, dibutyl sebacate, diethyl phthalate, glycerol, mono- or di-acetylation monoglyceride, propyleneglycol, triacetine, triethyl citrate and the like may be further added.
- When the polyethylene glycol-containing aqueous solution contains a component other than polyethylene glycol, the proportion of polyethylene glycol in the whole components (excluding water) is about 1 to about 30 wt %, preferably about 10 to about 20 wt %.
- For a treatment of the surface of a solid dosage form with a polyethylene glycol-containing aqueous solution, various coating methods generally used in the field of preparations can be employed. Preferably, spray coating is applied using a coating pan, a fluid bed coating system and the like.
- In the case of sugar-coated tablets, for example, after completion of each step of sugar coating (i.e., waterproof coating, under coating, sub-coating, coloring, finishing), tablets are transferred to a cloth polishing pan, a predetermined amount of a polyethylene glycol-containing aqueous solution is sprayed or poured thereon while rotating the pan, or a polyethylene glycol-containing aqueous solution is sprayed or poured thereon once to several times while rotating the pan until it reaches a predetermined coating weight.
- In the case of film-coated tablets, for example, a polyethylene glycol-containing aqueous solution is sprayed with a compressed air from a spray nozzle in the coating pan used for the film coating while rotating the pan, and the surface of the tablets is dried by heated air supplied. Alternatively, in the fluid bed coating system used for the film coating, a polyethylene glycol-containing aqueous solution is sprayed from a spray nozzle while floating or fluidizing the tablets with an air flow and the surface of the tablets is dried with the air flow. The polyethylene glycol-containing aqueous solution is sprayed in a predetermined amount, or the above-mentioned operation is repeated until a predetermined coat weight is achieved.
- In the case of plain tablets, namely, when a polyethylene glycol-containing aqueous solution also functions as a film coating liquid, a method employed for conventional film coating can be used directly. For example, a method similar to that of the above-mentioned film-coated tablets can be mentioned.
- In the case of capsule, too, a method employed for conventional film coating can be used similarly. When this treatment is applied after filling packing materials such as an active ingredient and the like, powder of the packing materials attached to the surface of the capsule during the filling is preferably removed with a conventional capsule polishing machine before the treatment.
- The weight of the coating film formed by the treatment method of the present invention is not particularly limited as long as it ensures that polyethylene glycol remains on the surface of a solid dosage form after treatment in an amount sufficient to improve the abrasion resistance of a print to be produced on said surface. Preferably, it is appropriately selected from the range that makes the weight ratio of the amount of polyethylene glycol to be added by this treatment to the finished preparation fall within the range of about 0.01 to about 1.0%, more preferably about 0.05 to about 0.7%.
- The treatment method of the present invention can not only improve the abrasion resistance of a print to be produced on the surface of a solid dosage form, but also reduce the frequency of printing failure (i.e., printing failure rate) during printing such as incomplete print, printing stain and the like, and advantageously further improve the printing performance as a whole.
- Accordingly, the present invention also relates to a production method of a solid dosage form having a print on its surface, which comprises treating the surface of the solid dosage form with a polyethylene glycol-containing aqueous solution and then printing on said surface. The treatment with a polyethylene glycol-containing aqueous solution can be applied as mentioned above.
- For printing, a method conventionally used in the art can be employed. As a solid dosage form delivery mechanism of a printing machine, any type can be used, including a slot type, a drum type, a link type and the like, and an appropriate type can be selected according to the manufacturing scale and the like. While the printing method is not particularly limited, either, a photogravure offset printing method is often used. To be specific, a photogravure roll engraved with an identification code, a symbol and the like during a photomechanical process is rotated in an ink tank to attach the ink, and redundant ink is scraped off with a blade (thin-bladed knife). The ink remaining in the engraving (concave) is transferred onto a rubber offset roll, and then transferred onto the solid dosage form in a printing section to complete the printing. As the tablet (capsule) printing machine, commercially available ones from Markem Corporation, Hartnett, Matsuoka Machinery Works Co., Ltd, Qualicaps Co., Ltd. and the like can be used.
- While the ink to be used for printing is not particularly limited as long as it is harmless, it is desirably quick-drying, and has high abrasion resistance after drying.
- As the dye, titanium oxide, carbon black, iron oxide, tar dyes (e.g., acidic colors such as Red No. 2, Red No. 3, Red No. 102, Red No. 104-(1), Red No. 105-(1), Red No. 106, Yellow No. 4, Yellow No. 5, Green No. 5, Blue No. 1, Blue No. 2 and the like) and the like are generally used. As the base agent, moreover, shellac and the like are used and, as the solvent, ethanol, n-butanol, isopropanol and the like are used.
- The solid dosage form with a print on its surface, which is produced by the above-mentioned method, has novel and useful characteristic in that it shows remarkably improved abrasion resistance of prints as compared to conventional preparations obtained by applying, before printing, a polishing treatment with a wax solution using an organic solvent or a powder wax or a wax-like substance. Accordingly, the present invention also provides a solid dosage form obtained by the above-mentioned method, which has a print on its surface.
- The solid dosage form of the present invention can be conferred a desirable characteristic of superior abrasion resistance of a print produced on its surface, due to the presence of a coating film containing polyethylene glycol on the surface of the solid dosage form. The “coating film” does not need to completely cover the surface of a solid dosage form, as long as polyethylene glycol is substantially uniformly present at least on the area to be printed on. For example, the “coating film” may be in the state where a number of miniature films attach to the surface of a solid dosage form. As used herein, by “substantially uniform” is meant being uniform to a degree sufficient to improve the abrasion resistance of the print. Therefore, the solid dosage form of the present invention is not restricted to the above-mentioned method, as long as it has the above-mentioned surface structure and superior abrasion resistance of the print, and may be produced by any method.
- Preferably, the solid dosage form of the present invention does not contain bees wax and carnauba wax in the coating film containing polyethylene glycol.
- The solid dosage form of the present invention can be administered to the subject in the same manner as in conventional solid dosage forms.
- The present invention is explained in detail in the following by referring to Examples, which are mere examples and do not limit the scope of the present invention in any way.
-
plain tablet 130.0 (containing 4 mg of active ingredient) hydroxypropylmethylcellulose 3.74 (74.8%) (TC-5; trademark) copolyvidon 0.75 (15.0%) titanium oxide 0.5 (10.0%) yellow ferric oxide 0.01 (0.2%) total 135.0 - Plain tablets were placed in a coating machine (Driacoater (Powrex Corporation) or Hicoater (Freund Corporation)), a film coating liquid containing TC-5, copolyvidon, titanium oxide and yellow ferric oxide at the above-mentioned weight ratios was sprayed with a spray nozzle while rotating the pan, and the tablets were dried by heated air supplied. This operation was repeated until the above-mentioned coating weight was achieved.
- Pre-printing Treatment with Polyethylene Glycol-containing Aqueous Solution Formulation (Unit: mg)
Prepar. Ex. 1 Prepar. Ex. 2 Comp. Ex. film-coated tablet 135.0 135.0 135.0 (Reference Example) MACROGOL 4000 0.1 (the Japan Pharmacopoeia) MACROGOL 6000 0.1 (the Japan Pharmacopoeia) water (0.9) (0.9) carnauba wax 0.008 sorbitan mono-oleate 0.04 n-hexane (0.9625) - The film-coated tablets (6,000 tablets, 810 g) obtained in the above-mentioned Reference Example were placed in a Hicoater (Freund Corporation), and a 10 wt % aqueous solution of MACROGOL 4000 (the Japan Pharmacopoeia; molecular weight 2,600-3,800) (Preparation Example 1) or MACROGOL 6000 (the Japan Pharmacopoeia; molecular weight 7,300-9,300) (Preparation Example 2) in total 6.0 g, or a 0.79 wt % carnauba wax n-hexane solution (Comparative Example) in total 6.063 g was sprayed with a spray nozzle while rotating the pan to give respective tablets having the above-mentioned formulations.
- The above-mentioned respective tablets were printed on by a conventional method using an organic solvent type ink (manufactured by Colorcon. Inc.) with a tablet printing machine (Matsuoka Machinery Works Co., Ltd).
- The three kinds of tablets (500 tablets each) obtained in the above-mentioned Example 2 were visually observed to examine printing failure, and 100 tablets each were placed in 3K glass bottles, which were shaken at amplitude 40 mm, shaking speed 250 times/minute in a reciprocal shaker SR-IIw (Nihon Medical and Chemical instruments Co., Ltd.) to observe the level of abrasion of the print over time. The results are shown in Table 1.
TABLE 1 Comp. Ex. Prep. Ex. 1 Prep. Ex. 2 appear- number of 500 500 500 ance test tablets Class D 0 0 0 (%)1) Class C 0 0 0 (%) Class B in- 2.0 0 0 (%) complete print printing 1.4 1.2 0.8 stain total 3.4 1.2 0.8 abrasion 10 min print is no change (±) no change (±) property2) scratchy, whole tablet is stained (+) 30 min print is print is no change (±) scratchy, scratchy, whole whole tablet is tablet is stained (++) stained (+) 60 min print is print is print is scratchy, scratchy, scratchy, whole whole whole tablet is tablet is tablet is stained (+++) stained, stained, cloudy cloudy bottle (++) bottle (++)
1)Class of appearance
Class B: readable print though partly missing, or printing stain of not more than 1 mm in length
Class C: partly unreadable print, or printing stain of more than 1 mm in length
Class D: unreadable print
2)Abrasion property
(±): No change from the start of shaking
(+): readable print though with slight change in printing state (scratching, stain and the like)
(++): clear change in printing state and partly unreadable print
(+++): marked change in printing state and mostly unreadable print
- As is clear from Table 1, a pretreatment with a polyethylene glycol-containing aqueous solution resulted in remarkably improved abrasion resistance of the print as compared to the use of carnauba wax. Moreover, the printing failure rate showed a tendency toward lower levels. More superior results were obtained in both the abrasion resistance and printing failure rate by the use of MACROGOL 6000.
- According to the treatment method of the present invention, printability and abrasion resistance of a print to be produced on a surface of the solid dosage form can be improved, and as a result, identification function of the solid dosage form can be maintained for a long time and good appearance is not impaired, and a solid dosage form with a high commercial value can be provided.
- The method for treating a solid dosage form of the present invention provides an effect of remarkably improved printability and abrasion resistance of the solid dosage form by treating, before printing, the surface of the solid dosage form with a polyethylene glycol-containing aqueous solution.
- While some of the embodiments of the present invention have been described in detail in the above, it is, however, possible for those of ordinary skill in the art to make various modifications and changes to the particular embodiments shown without substantially departing from the teaching and advantages of the present invention. Such modifications and changes are encompassed in the spirit and scope of the present invention as set forth in the appended claims.
- Those described in a singular form in the present specification may be understood in a plural form, as long as they are not associated with clear inconsistencies with the context and the present invention.
- All references cited herein, including patents and patent applications, are hereby incorporated in full by reference, to the extent that they have been disclosed herein.
- This application is based on a patent application No. 2003-401691 filed in Japan, the contents of which are incorporated in full herein by this reference.
Claims (21)
1. A treatment method for improving printability or abrasion resistance of a print to be produced on a surface of a solid dosage form, which comprises treating said surface with a polyethylene glycol-containing aqueous solution before printing.
2. The method of claim 1 , wherein polyethylene glycol has an average molecular weight of not less than about 1,000.
3. The method of claim 1 , wherein polyethylene glycol has an average molecular weight of about 3,000 to about 9,000.
4. The method of claim 1 , wherein the amount of polyethylene glycol to be added by the treatment is about 0.01% to about 1.0% in a weight ratio to the finished preparation.
5. The method of claim 1 , wherein the solid dosage form is a film-coated tablet.
6. A method for producing a solid dosage form with a printed surface, which comprises treating the surface of the solid dosage form with a polyethylene glycol-containing aqueous solution and then printing on said surface.
7. The method of claim 6 , wherein polyethylene glycol has an average molecular weight of not less than about 1,000.
8. The method of claim 6 , wherein polyethylene glycol has an average molecular weight of about 3,000 to about 9,000.
9. The method of claim 6 , wherein the amount of polyethylene glycol to be added by the treatment is about 0.01% to about 1.0% in a weight ratio to the finished preparation.
10. The method of claim 6 , wherein the solid dosage form is a film-coated tablet.
11. A solid dosage form treated by the method of claim 1 .
12. A solid dosage form with a printed surface, which can be obtained by the method of claim 6 .
13. A solid dosage form which has a coating film comprising polyethylene glycol but free of bees wax and carnauba wax on its surface, and is printed on the surface of the coating film.
14. A solid dosage form treated by the method of claim 2 .
15. A solid dosage form treated by the method of claim 3 .
16. A solid dosage form treated by the method of claim 4 .
17. A solid dosage form treated by the method of claim 5 .
18. A solid dosage form with a printed surface, which can be obtained by the method of claim 7 .
19. A solid dosage form with a printed surface, which can be obtained by the method of claim 8 .
20. A solid dosage form with a printed surface, which can be obtained by the method of claim 9 .
21. A solid dosage form with a printed surface, which can be obtained by the method of claim 10.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/659,630 US9149437B2 (en) | 2003-12-01 | 2010-03-15 | Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-401691 | 2003-12-01 | ||
JP2003401691 | 2003-12-01 | ||
PCT/JP2004/018112 WO2005053599A1 (en) | 2003-12-01 | 2004-11-30 | Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/018112 A-371-Of-International WO2005053599A1 (en) | 2003-12-01 | 2004-11-30 | Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/659,630 Continuation US9149437B2 (en) | 2003-12-01 | 2010-03-15 | Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070116764A1 true US20070116764A1 (en) | 2007-05-24 |
Family
ID=34649985
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/581,071 Abandoned US20070116764A1 (en) | 2003-12-01 | 2004-11-30 | Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
US12/659,630 Expired - Lifetime US9149437B2 (en) | 2003-12-01 | 2010-03-15 | Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/659,630 Expired - Lifetime US9149437B2 (en) | 2003-12-01 | 2010-03-15 | Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing |
Country Status (5)
Country | Link |
---|---|
US (2) | US20070116764A1 (en) |
EP (1) | EP1700591A4 (en) |
JP (1) | JP4999329B2 (en) |
CA (1) | CA2547594A1 (en) |
WO (1) | WO2005053599A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
US20160367566A1 (en) * | 2015-06-19 | 2016-12-22 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for anesthesiological applications |
US10166240B2 (en) | 2015-06-19 | 2019-01-01 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
US10179136B2 (en) | 2015-06-19 | 2019-01-15 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
US10391102B2 (en) | 2015-06-19 | 2019-08-27 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
US10555952B2 (en) | 2015-06-19 | 2020-02-11 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
US12083126B2 (en) | 2015-06-19 | 2024-09-10 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5614826B2 (en) * | 2005-07-13 | 2014-10-29 | 塩野義製薬株式会社 | Formulation with suppressed fading |
DE102011088909A1 (en) | 2011-08-12 | 2013-02-14 | Labtec Gmbh | Process for the preparation and control of oral drug films |
JP5916091B2 (en) * | 2012-01-31 | 2016-05-11 | 大原薬品工業株式会社 | UV laser printing method for orally disintegrating tablets |
JP6417647B2 (en) * | 2013-06-21 | 2018-11-07 | 凸版印刷株式会社 | Method for producing a solid preparation substrate |
JP6755165B2 (en) * | 2016-11-14 | 2020-09-16 | 株式会社Screenホールディングス | Pigment fixing composition and solid preparation |
JP2018177810A (en) * | 2018-07-13 | 2018-11-15 | 凸版印刷株式会社 | Solid preparation ink and solid preparation printed object |
JP7263047B2 (en) * | 2019-02-25 | 2023-04-24 | 沢井製薬株式会社 | film coated tablets |
JP7623627B2 (en) | 2019-08-28 | 2025-01-29 | 小野薬品工業株式会社 | Solid dosage forms with printing on the film coating |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3751277A (en) * | 1971-03-24 | 1973-08-07 | Dow Chemical Co | Tablet coating process and composition |
US4456629A (en) * | 1982-07-12 | 1984-06-26 | E. R. Squibb & Sons, Inc. | Powdered wax, tablet coated therewith and method |
US4482387A (en) * | 1982-07-12 | 1984-11-13 | E. R. Squibb & Sons, Inc. | Powdered wax, tablet coated therewith and method |
US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
US20010046517A1 (en) * | 2000-04-26 | 2001-11-29 | Hiroyasu Kokubo | Solid preparation coated with a film coating layer and film coating agent |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5927325B2 (en) * | 1976-10-25 | 1984-07-05 | 住友化学工業株式会社 | Method for manufacturing printed dragees |
JPS54138118A (en) * | 1978-04-19 | 1979-10-26 | Sumitomo Chem Co Ltd | Manufacturing of glossy, printed sugar-coated tablet |
JPS58152813A (en) | 1982-03-08 | 1983-09-10 | Sumitomo Chem Co Ltd | Tablets with clear markings and their manufacturing method |
SK282071B6 (en) | 1991-01-30 | 2001-10-08 | The Wellcome Foundation Limited | Water-dispersible tablet and its preparation method |
GB9215908D0 (en) | 1992-07-27 | 1992-09-09 | Wellcome Found | Water dispersible tablets |
US5314697A (en) * | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
AU5655196A (en) | 1995-05-09 | 1996-11-29 | Colorcon Limited | Powder coating composition for electrostatic coating of pharmaceutical substrates |
AU4040800A (en) | 1999-03-29 | 2000-10-16 | American Home Products Corporation | Coating system |
WO2001045668A2 (en) * | 1999-12-20 | 2001-06-28 | Schering Corporation | Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
JP4700833B2 (en) * | 2000-04-26 | 2011-06-15 | 信越化学工業株式会社 | Method for producing solid preparation coated with film coating layer and solid preparation processing apparatus |
-
2004
- 2004-11-30 JP JP2005516013A patent/JP4999329B2/en not_active Expired - Lifetime
- 2004-11-30 US US10/581,071 patent/US20070116764A1/en not_active Abandoned
- 2004-11-30 CA CA 2547594 patent/CA2547594A1/en not_active Abandoned
- 2004-11-30 WO PCT/JP2004/018112 patent/WO2005053599A1/en not_active Application Discontinuation
- 2004-11-30 EP EP04799960A patent/EP1700591A4/en not_active Withdrawn
-
2010
- 2010-03-15 US US12/659,630 patent/US9149437B2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3751277A (en) * | 1971-03-24 | 1973-08-07 | Dow Chemical Co | Tablet coating process and composition |
US4456629A (en) * | 1982-07-12 | 1984-06-26 | E. R. Squibb & Sons, Inc. | Powdered wax, tablet coated therewith and method |
US4482387A (en) * | 1982-07-12 | 1984-11-13 | E. R. Squibb & Sons, Inc. | Powdered wax, tablet coated therewith and method |
US6254888B1 (en) * | 2000-01-28 | 2001-07-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for coating pharmaceutical dosage forms |
US20010046517A1 (en) * | 2000-04-26 | 2001-11-29 | Hiroyasu Kokubo | Solid preparation coated with a film coating layer and film coating agent |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
US10166240B2 (en) | 2015-06-19 | 2019-01-01 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
WO2016205533A1 (en) * | 2015-06-19 | 2016-12-22 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for anesthesiological applications |
KR20180014828A (en) | 2015-06-19 | 2018-02-09 | 임프리미스 파마슈티컬스 인코포레이티드 | Pharmaceutical composition for anesthesia |
US9918993B2 (en) * | 2015-06-19 | 2018-03-20 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for anesthesiological applications |
US20160367566A1 (en) * | 2015-06-19 | 2016-12-22 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for anesthesiological applications |
US10179136B2 (en) | 2015-06-19 | 2019-01-15 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
AU2016280161B2 (en) * | 2015-06-19 | 2019-02-21 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions for anesthesiological applications |
KR101964571B1 (en) * | 2015-06-19 | 2019-04-02 | 해로우 헬스 인코포레이티드 | Pharmaceutical composition for anesthesia |
US10391102B2 (en) | 2015-06-19 | 2019-08-27 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
US10555952B2 (en) | 2015-06-19 | 2020-02-11 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
US12083126B2 (en) | 2015-06-19 | 2024-09-10 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for anesthesiological applications |
Also Published As
Publication number | Publication date |
---|---|
CA2547594A1 (en) | 2005-06-16 |
EP1700591A4 (en) | 2011-08-03 |
JP4999329B2 (en) | 2012-08-15 |
JPWO2005053599A1 (en) | 2007-06-28 |
EP1700591A1 (en) | 2006-09-13 |
US9149437B2 (en) | 2015-10-06 |
US20110014130A1 (en) | 2011-01-20 |
WO2005053599A1 (en) | 2005-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9149437B2 (en) | Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing | |
EP0573462B1 (en) | A method of highlighting intagliations in tablets | |
US8309104B2 (en) | Oral controlled release formulation for sedative and hypnotic agents | |
US20040028737A1 (en) | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same | |
US5830503A (en) | Enteric coated diltiazem once-a-day formulation | |
RU2375048C2 (en) | Pharmacological composition with swelling coating | |
US6503535B2 (en) | Method for coating pharmaceutical dosage forms | |
KR20010074914A (en) | Omeprazole formulation | |
HU219350B (en) | Stabilizing acryl-polimer-type coating compositions for controlling release of drug and process for production its | |
EP1677766B1 (en) | Pharmaceutical agent-containing formulation comprising a coating | |
JPH0262822A (en) | Membrane coated tablet | |
RU2311906C2 (en) | Composition of sustained-release preparation for releasing of acid secretion inhibitor in stomach and method for production thereof | |
US20070141150A1 (en) | Pharmaceutical composition | |
MXPA06000577A (en) | Pharmaceutical compositions having a swellable coating. | |
CN112048214A (en) | Coating composition for ink-jet printing on to form marking agent, aqueous ink marking agent and method for preparing marking agent | |
DK171127B1 (en) | The ranitidine tablet with a hydroxypropylmethylcellulose-containing coating as well as a method for providing this coating | |
JP7623627B2 (en) | Solid dosage forms with printing on the film coating | |
Hemchand et al. | Recent advances in different aspects of tablet coating | |
JP7573565B2 (en) | Film-coated tablets bearing labels and their manufacturing method | |
US20240285539A1 (en) | Protective coating for moisture sensitive pharmaceutical compositions | |
JPS625403B2 (en) | ||
RU2609198C1 (en) | Solid drug form of imipramine with immediate release and method of obtaining thereof | |
JP2002370971A (en) | Method for producing stable enteric-coated sugar-coated tablets | |
KR20160137507A (en) | Solid preparation for coating agent, and film and coated solid preparation formed from same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARUNAKA, SHIGEYUKI;FUKUYAMA, HIKARU;FUKADA, HIROSHI;AND OTHERS;REEL/FRAME:017974/0418 Effective date: 20060515 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |